Navin Fluorine International Limited

rs,

October 30, 2025 BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai 400001 Scrip Code: 532504 Dear Sir / Madam, National Stock Exchange

Rs. 758.4

s and projections. 2 Q2 & H1 FY26 Financial Performance Q2FY26 - Performance at a glance Sales Rs. 758.4 Crs + 46% Y-o-Y Operating EBITDA Rs. 246.2 Crs + 129% Y-o-Y Operating EBITDA Margin 32.5% + 117

46%

. 2 Q2 & H1 FY26 Financial Performance Q2FY26 - Performance at a glance Sales Rs. 758.4 Crs + 46% Y-o-Y Operating EBITDA Rs. 246.2 Crs + 129% Y-o-Y Operating EBITDA Margin 32.5% + 1176 bps Y-o-

Rs. 246.2

Performance Q2FY26 - Performance at a glance Sales Rs. 758.4 Crs + 46% Y-o-Y Operating EBITDA Rs. 246.2 Crs + 129% Y-o-Y Operating EBITDA Margin 32.5% + 1176 bps Y-o-Y Operating PBT Rs. 179.3 Crs + 1

129%

Y26 - Performance at a glance Sales Rs. 758.4 Crs + 46% Y-o-Y Operating EBITDA Rs. 246.2 Crs + 129% Y-o-Y Operating EBITDA Margin 32.5% + 1176 bps Y-o-Y Operating PBT Rs. 179.3 Crs + 173% Y-o-Y

32.5%

s Rs. 758.4 Crs + 46% Y-o-Y Operating EBITDA Rs. 246.2 Crs + 129% Y-o-Y Operating EBITDA Margin 32.5% + 1176 bps Y-o-Y Operating PBT Rs. 179.3 Crs + 173% Y-o-Y + 5% Q-o-Q + 19% Q-o-Q + 395 bps Q

1176 bps

.4 Crs + 46% Y-o-Y Operating EBITDA Rs. 246.2 Crs + 129% Y-o-Y Operating EBITDA Margin 32.5% + 1176 bps Y-o-Y Operating PBT Rs. 179.3 Crs + 173% Y-o-Y + 5% Q-o-Q + 19% Q-o-Q + 395 bps Q-o-Q + 27%

Rs. 179.3

EBITDA Rs. 246.2 Crs + 129% Y-o-Y Operating EBITDA Margin 32.5% + 1176 bps Y-o-Y Operating PBT Rs. 179.3 Crs + 173% Y-o-Y + 5% Q-o-Q + 19% Q-o-Q + 395 bps Q-o-Q + 27% Q-o-Q 6 2 Y F 2 Q Revenue Gr

173%

Crs + 129% Y-o-Y Operating EBITDA Margin 32.5% + 1176 bps Y-o-Y Operating PBT Rs. 179.3 Crs + 173% Y-o-Y + 5% Q-o-Q + 19% Q-o-Q + 395 bps Q-o-Q + 27% Q-o-Q 6 2 Y F 2 Q Revenue Growth (Y-o-Y

5%

-o-Y Operating EBITDA Margin 32.5% + 1176 bps Y-o-Y Operating PBT Rs. 179.3 Crs + 173% Y-o-Y + 5% Q-o-Q + 19% Q-o-Q + 395 bps Q-o-Q + 27% Q-o-Q 6 2 Y F 2 Q Revenue Growth (Y-o-Y) HPP 38%

19%

ing EBITDA Margin 32.5% + 1176 bps Y-o-Y Operating PBT Rs. 179.3 Crs + 173% Y-o-Y + 5% Q-o-Q + 19% Q-o-Q + 395 bps Q-o-Q + 27% Q-o-Q 6 2 Y F 2 Q Revenue Growth (Y-o-Y) HPP 38% Consolidated

395 bps

gin 32.5% + 1176 bps Y-o-Y Operating PBT Rs. 179.3 Crs + 173% Y-o-Y + 5% Q-o-Q + 19% Q-o-Q + 395 bps Q-o-Q + 27% Q-o-Q 6 2 Y F 2 Q Revenue Growth (Y-o-Y) HPP 38% Consolidated Financials Speci

“• Validation batches started in cGMP4, supplies targeted by Jan 26 Strong outlook with 3 years projection •”

“• EU Major – Supplies concluded for the material order in Q2 FY26 and in discussion for the future supplies • Another EU Major – Scale up order received for supplies in Q3 & Q4 FY26 • Based on the successful deliveries of late-stage pipeline molecules, plant was audited by three global major innovators 9 Consolidated Profitability Statement Particulars (Rs.”

“28 Investing in community well-being Total CSR expenditure for FY25 Rs.”

European CDMO MSA

1

Strategy -in-action

1

Resilient business model

1

CSR contribution made to

1

Investor Relations Advisors

1

European CDMO MSA

• Validation batches started in cGMP4, supplies targeted by Jan 26 Strong outlook with 3 years projection •

Strategy -in-action

• EU Major – Supplies concluded for the material order in Q2 FY26 and in discussion for the future supplies • Another EU Major – Scale up order received for supplies in Q3 & Q4 FY26 • Based on the successful deliveries of late-stage pipeline molecules, plant was audited by three global major innovators 9 Consolidated Profitability Statement Particulars (Rs. Crs) Net Revenue From Operations Raw Material Employee Expenses Other Expenses Operating EBITDA Operating EBITDA Margin Interest Expenses Depreciation Operating PBT Operating PBT Margin Other Income Profit Before Tax Tax Profit After Tax (Loss) From Associates And Joint Venture (Net) Other Comprehensive Income Items That Will Not Be Reclassified To Profit & Loss (Net Of Tax) Items that may be reclassified to profit and loss Total Comprehensive Income For The Period *Amounts are below rounding off norms adopted by the Group Q2 FY26 Q2 FY25 758.42 312.90 73.04 126.31 246.17 518.56 223.98 76.95 110.28 107.35 Y-o-Y Change % 46.26% 129.3

Resilient business model

diversified divisions, products, plants & end markets 3 Geographies 4 Countries 3 Business Verticals 4 Factories 3 R&D Centres 5 Sales Offices 900+ Total Customers 1,498 Total Employees Preferred source and a partner of choice for diverse fluorochemical solutions globally Leveraging our fluorochemicals expertise, world-class manufacturing facilities, dynamic in-house R&D, advanced technologies and competent workforce, we have developed a comprehensive and diversified portfolio, encompassing: Specialty Chemicals As on March 31st 2025 HPP CDMO 17 3P approach to building capacities, building scalable platforms and nurturing long- term partnerships Diverse portfolio including fluorine- based intermediates, specialty chemicals and inorganic chemicals Product 3P FOCUS Partnerships Platform Forging multiyear partnerships to integrate within the global supply chain positioning alongside industry majors Harnessing their expertise and resources to expand our reach and scale with impact Focus on

CSR contribution made to

SHRI SADGURU SEVA SANGH TRUST ACT-EVE FOUNDATION CHARUTAR AROGYA MANDAL SHALA PRAVESHOTSAV BLIND PEOPLE’S ASSOCIATION CANCER PATIENT AID ASSOCIATION FOUNDATION FOR PROMOTION OF SPORTS KC MAHINDRA EDUCATION TRUST SIR J.J. HOSPITAL SHAKTI FOUNDATION CONSUMER EDUCATION AND RESEARCH CENTRE MOBILE HEALTH VANS 29 Track record of progressive dividends Dividend as % of Face Value Special Final Interim Payout %* 750% 600% 65% 85% FY12 140% 75% 65% FY10 150% 85% 65% FY11 750% 150% 550% 550% 550% 600% 600% 500% 150% 390 200% 180% 150% 400% 315% 75% 130% 210% 110% 100% 110% 170% 190% 300% 300% 350% 350% 350% 325% 250% 250% 250% 250% 250% FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26 150% 75% 75% FY13 160% 160% 85% 75% FY14 85% 75% FY15 22% 24% 37% 40% 36% 38% 29% 28% 33% 31% 30% 23% 20% 19% 32% 25% * On standalone basis 30 For further information, please contact: Navin Fluorine International Ltd. CIN : L24110MH1998PLC115499 anish.ganatra@nfil.in Mr. Anish Ganatra Chief Financial Officer a

Investor Relations Advisors

MUFG Intime India Private Limited A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services Ms. Payal Dave payal.dave@in.mpms.mufg.com payal.dave@in.mpms.mufg.com Ms. Pooja Swami pooja.swami@in.mpms.mufg.com pooja.swami@in.mpms.mufg.com Meeting Request Link LinkLink